Gritstone bio

Gritstone bio is a clinical-stage biotech company founded in 2015 and headquartered in the United States. The company's slogan reflects its ambition to develop the world’s most potent vaccines for cancer and infectious disease. With a focus on tumor-specific neoantigens and viral antigens displayed on the surface of virus-infected cells, Gritstone bio aims to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens. The company has brought together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team, and a seasoned and successful board of directors. Gritstone bio's unique approach to immuno-oncology and infectious diseases addresses the biology underlying immune system recognition of targets on the surface of abnormal cells, which is common to both anti-tumor and anti-viral immunity. As a result, the company believes that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients. Gritstone bio recently secured a $32.50M Post-IPO Equity investment on 01 April 2024. The investors behind this latest investment round are not disclosed. Gritstone bio operates in the Biotechnology and Health Care industries, positioning itself at the forefront of cutting-edge innovation in the development of vaccines for critical medical needs.